Investment accounts
Adult accounts
Child accounts
Choosing Fidelity
Choosing Fidelity
Why invest with us Current offers Fees and charges Open an account Transfer investments
Financial advice & support
Fidelity’s Services
Fidelity’s Services
Financial advice Retirement Wealth Management Investor Centre (London) Bereavement
Guidance and tools
Guidance and tools
Choosing investments Choosing accounts ISA calculator Retirement calculators
Share dealing
Choose your shares
Tools and information
Tools and information
Share prices and markets Chart and compare shares Stock market news Shareholder perks
Pensions & retirement
Pensions, tax & tools
Saving for retirement
Approaching / In retirement
Approaching / In retirement
Speak to a specialist Creating a retirement plan Taking tax-free cash Pension drawdown Annuities Investing in retirement Investment Pathways
Pfizer ups full-year earnings outlook
(Sharecast News) - Pfizer raised its full-year earnings forecast on Wednesday, on the back of solid demand for its non-Covid products. The US drugs giant, which saw sales and profits rocket during the pandemic due to strong demand for its Covid-19 vaccine Comirnaty, said revenues fell 20% in the first quarter to $14.9bn.
First-quarter sales from Comirnaty fell 88% to $354m, as demand for the vaccine continued to wane, below expectations for around $496m.
However, Pfizer insisted the decline was in line with internal expectations. It also noted that around 90% of vaccine sales are expected to occur in the second half, mainly in the fourth quarter.
Sales of Covid antiviral treatment Paxlovid also beat expectations, falling 50% to $2bn.
Once contributions from Comirnaty and Paxlovid were stripped out, revenues rose 11% operationally.
Reported net income tumbled 44% to $3.1bn, while adjusted diluted earnings per share fell 33% to $0.82.
But David Denton, chief financial officer, said: "I am very pleased by the strong 11% operational revenue growth of our non-Covid products in the first quarter, demonstrating our focus on commercial execution.
"In addition, we continue to progress our cost-realignment programme and remain on track to deliver on our targeted cost savings goal by the end of the year."
Pfizer therefore lifted its forecast for adjusted diluted EPS for the full-year to between $2.15 and $2.35, up from between $2.05 and $2.25 previously.
All other forecasts were left unchanged, including plans to deliver "at least" $4bn in net cost savings by the year end.
Albert Bourla, chief executive, said: "We delivered strong performance in our non-Covid product portfolio in the first quarter, including increased revenue from several of our recent commercial launches and acquired products, as well as robust growth for several key in-line brands.
"Overall I am encouraged by the well-executed quarter, setting the tone for the year."
Share this article
Related Sharecast Articles
Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.
Award-winning online share dealing
Search, compare and select from thousands of shares.
Expert insights into investing your money
Our team of experts explore the world of share dealing.
Policies and important information
Accessibility | Conflicts of interest statement | Consumer Duty Target Market | Consumer Duty Value Assessment Statement | Cookie policy | Diversity, Equity & Inclusion | Doing Business with Fidelity | Diversity, Equity & Inclusion Reports | Investing in Fidelity funds | Legal information | Modern slavery | Mutual respect policy | Privacy statement | Remuneration policy | Staying secure | Statutory and Regulatory disclosures | Whistleblowing policy
Please remember that past performance is not necessarily a guide to future performance, the performance of investments is not guaranteed, and the value of your investments can go down as well as up, so you may get back less than you invest. When investments have particular tax features, these will depend on your personal circumstances and tax rules may change in the future. This website does not contain any personal recommendations for a particular course of action, service or product. You should regularly review your investment objectives and choices and, if you are unsure whether an investment is suitable for you, you should contact an authorised financial adviser. Before opening an account, please read the ‘Doing Business with Fidelity’ document which incorporates our client terms. Prior to investing into a fund, please read the relevant key information document which contains important information about the fund.
This website is issued by Financial Administration Services Limited, which is authorised and regulated by the Financial Conduct Authority (FCA) (FCA Register number 122169) and registered in England and Wales under company number 1629709 whose registered address is Beech Gate, Millfield Lane, Lower Kingswood, Tadworth, Surrey, KT20 6RP.